Dhiti Omics

What Dhiti Omics does

Dhiti Omics Technologies Private Ltd is a precision molecular diagnostics provider headquartered in Bengaluru, India. Founded in 2015 as an associate organization of Genotypic Technology—India's pioneering genomics services firm co-founded by Dr. Sudha N. Rao in 1998—the company offers a comprehensive portfolio of genetic testing services to hospitals, clinics, nursing homes, individual patients, and, during the COVID-19 pandemic, educational institutions and workplaces. Its primary clinical customers are healthcare providers seeking diagnostic resolution in cases of suspected-but-undiagnosed or partially diagnosed genetic conditions.

The company's product portfolio spans Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), CGH-Microarray, and Sanger Sequencing, complemented by specialty panels covering neurological, cardiac, neuromuscular, metabolic, endocrine, renal, mitochondrial, and inherited cancer disorders, plus pre-natal, carrier, thalassemia, and sickle cell screening. It also offers infectious disease PCR panels (HIV, HBV, HCV, HPV), AML/ALL leukemia PCR panels, BCR-ABL quantitative testing, and Fuvibact—a Nanopore-based metagenomic assay for pathogen identification and antimicrobial resistance profiling with 24–36 hour turnaround. In 2020 the firm launched a COVID-19 testing suite including NABL-accredited RT-PCR, the TataMD CHECK CRISPR-based test, Rapid Antigen Testing, and the Tapestry pooled-testing algorithm developed in partnership with Algorithmic Biologics.

Dhiti Omics generates revenue through one-time per-test fees with quote-based, non-publicly-disclosed pricing across its genetic and infectious disease menus. Its go-to-market combines B2B direct sales to healthcare institutions, an online appointment-booking portal for individual consumers, event-driven engagement through medical conferences and CME programs (including work with Apollo Hospital Hyderabad), and on-site testing for institutional clients. The laboratory holds NABL accreditation (Lab MC-4316) and ICMR approval (Registration No: DHOMTBK) for COVID-19 testing, while R&D operations leverage the DSIR-certified and ISO 9001-2008 certified infrastructure of Genotypic Technology.

Name

Dhiti Omics

Legal name

Dhiti Omics Technologies Private Ltd

Website

https://dhitiomics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Dhiti Omics Technologies Private Ltd is a Bengaluru-based molecular diagnostics company providing genetic and infectious disease testing—including WGS, WES, specialty disease panels, and COVID-19 assays—to hospitals, clinics, and individual patients across India.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics and Genetic Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Genetic & Prenatal Testing Laboratories (HLAFAMAH)

akta.pro secondary industries

Microbiology & Infectious Disease Testing Laboratories (HLAFAMAD), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

Keywords

• Genetic testing services
• Molecular diagnostics
• Next generation sequencing
• Clinical genomics
• Covid diagnostic testing

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Genetic Diagnostic Testing Services: One-time diagnostic testing services for various genetic conditions including rare diseases, inherited disorders, oncology panels, and infectious diseases. Revenue generated per test based on the specific assay performed.
2. COVID-19 Testing: RT-PCR, Rapid Antigen Testing, TataMD CHECK, and pooled testing services for SARS-CoV-2 detection. Services offered to hospitals, clinics, educational institutions, and individuals.
3. Educational and Conference Services: Sponsorship and participation in medical conferences, workshops, and CME programs where they present research and educate healthcare professionals.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Dhiti Omics operates an accredited molecular diagnostics laboratory that delivers genetic and infectious disease testing services to clinicians, hospitals, and patients. Its portfolio spans whole genome and exome sequencing, disease-specific panels (oncology, neurology, cardiology, metabolic, renal, prenatal), Sanger validation, CGH-microarray, infectious disease PCR panels, and COVID-19 diagnostics (RT-PCR, Rapid Antigen, TataMD CHECK CRISPR test, and pooled Tapestry screening). The Fuvibact metagenomics assay adds rapid pathogen and antimicrobial resistance identification using Nanopore sequencing.

Product overview

Dhiti Omics is a molecular diagnostics company offering a comprehensive portfolio of genetic testing services. The core offering includes Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES) for rare disease diagnosis using Next-Generation Sequencing technology, complemented by specialized disease-specific panels covering neurology, cardiology, oncology, metabolic disorders, endocrinology, nephrology, and neuromuscular conditions. The company also provides COVID-19 diagnostic solutions including RT-PCR testing, Rapid Antigen Testing, TataMD CHECK CRISPR-based testing, and pooled testing via the Tapestry platform. Infectious disease testing includes HIV, HBV, HCV, and HPV panels. Support services include Fuvibact (Nanopore-based metagenomics), carrier testing, thalassemia testing, single gene sequencing, data reanalysis, and genetic counselling. The portfolio utilizes technologies including NGS, Sanger sequencing, microarray, RT-PCR, and Nanopore sequencing.

Differentiator

Problem solved

Functional benefit

Products and services

• Whole Genome Sequencing (WGS) Comprehensive Next-Generation Sequencing screening for rare genetic disorders enabling prognosis, diagnosis, prevention, and therapy modulation. Sold to clinicians and healthcare providers.
• Whole Exome Sequencing (WES) Exome-region sequencing service for prognosis, diagnosis, prevention, and therapy modulation across a broad set of genetic conditions.
• Disease-Specific Genetic Panels Targeted genetic panels covering Hirschsprung disease, mitochondrial, metabolic, endocrine, cardiac, neurological, neuromuscular, renal, inherited cancer, leukemia (AML/ALL/BCR-ABL), and pre-natal/maternal-cell-contamination validation, sold to clinicians and hospitals.
• CGH-Microarray Microarray-based copy number variation detection for developmental delays, mental retardation, and related genetic conditions.
• Single Gene Sequencing (Sanger / Nanopore)

Quantifiable outcome

• Detection of genetic pre-disposition in inherited disorders
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature8 records

Partnerships

Two partnerships are on record, tiered core.

• Algorithmic BiologicscoreStrategic or Co-development Partner · 1 September 2023Dhiti Omics is partnering with Algorithmic Biologics to advance genetic research and molecular diagnostic discovery. Together they are working on groundbreaking advancements in genetics including pooled testing using Tapestry mathematical pooling algorithm for campus screening.
• Genotypic TechnologycoreStrategic or Co-development PartnerDhiti Omics is an associate organization of Genotypic Technology - the company that pioneered genomics services in India. Supported by Genomics Labs @ Genotypic Technology which holds DSIR certification, ISO 9001-2008 certification, and is India's first Certified Service Provider for Ion Torrent PGM and Agilent Certified Service Provider for SureSelect Target enrichment systems.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Apollo Diagnostics: Diagnostics arm of Apollo Hospitals offering pathology and specialty molecular testing across India. Leverages the Apollo hospital network for clinical referrals and institutional test volume.
• Dr. Lal PathLabs: India's largest listed diagnostics chain offering pathology and increasingly molecular/genetic testing through its network. Broad incumbent with national infrastructure that competes for hospital and patient testing volume.
• Thyrocare Technologies: High-volume, low-cost Indian diagnostics chain offering preventive and routine testing with growing molecular diagnostics capacity. Competes on cost efficiency in the institutional and preventive screening segments.
• Agilus Diagnostics (SRL Diagnostics): One of India's largest diagnostic laboratory networks offering comprehensive pathology and molecular diagnostics including genetic testing. Broad incumbent with pan-India reach; competes on hospital contracts and test menu breadth.

Emerging players

• Xcode Life Sciences: India-based DTC-focused genetic testing company offering preventive genomics and wellness panels. Comparable in NGS technology but competes primarily through direct-to-consumer channels rather than clinical B2B.
• Oncquest Laboratories: India-based specialty diagnostics lab focused on oncology molecular testing including BCR-ABL, leukemias, and hereditary cancer panels. Overlaps with Dhiti's oncology testing menu and serves similar hospital customers.

Direct peers

• MedGenome: India- and US-based genomics diagnostics company offering NGS-based genetic testing, inherited disease panels, and oncology diagnostics. Most directly comparable peer given similar technology platforms and Indian footprint.
• Genotypic Technology: Parent/associate organization providing genomics services and lab infrastructure to Dhiti Omics. Offers microarray, NGS, and Sanger sequencing services with similar scientific leadership and technology platforms.
• Mapmygenome: India-based molecular diagnostics company offering predictive genomic tests, including whole exome sequencing and clinical panels. Comparable Indian genomics services competitor with similar B2B and DTC channels.
• Strand Life Sciences: India-based genomics and bioinformatics company offering clinical diagnostics, genetic testing, and genomic research services. Comparable in technology stack and Indian clinical customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/dhitiomics
• Xx.com/dhitiomics

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dhiti Omics